All rights of articles and photos on this website are reserved.
Last Calling: 感兴趣的同学请于4月26号前将创业项目简介 (300-500字，或slides) 发送至 CSSA@HMS-CSSA.ORG
时间： 04/30/2017 (星期日)
地点：Folkman Auditorium, Enders Building, Children’s Hospital Boston
320 Longwood Ave, Boston, MA 02155
Alan Jiang, PhD, Chief Strategy Officer, XtalPi
Xiaoyu Tian, PhD, Vice President of Product Development, VcanBio
Title：Entrepreneurship in Medicine: Some Personal Lessons and Observations
Jeff Clark, J.D. & M.D. Associate at DLA Piper
Title: Intellectual Property Protection in USA
(Taking example of the gene editing Crispr/Cas9 patent)
Chesley Chen, CEO, Saftypartners, USA
Title: Zen and the Art of CEO Maintenance
Chesley Chen(Modulator), Alan Jiang, Xiaoyu Tian, Jeff Clark
项目路演（10 min presentation + 5 min Q&A）
Mr. Han-kai Yi, Vice General Manager, TusPark
Title: Global Talent for a Chinese Dream, Together Here for a Stronger
1:00 pm-1:10 pm
1:10 pm-2:00 pm:
目前确认的受邀嘉宾包括: Tus-holdings （启迪控股）; Yongjin Group （涌金集团）；Legend Capital （君联资本）；CSC Group （中科招商）；Wuxi Healthcare Venture （毓承资本）；Simcere（先声药业）；GeneChem（吉凯基因）等等
Alan Jiang, PhD
Yide Alan Jiang oversees global market positioning and strategy development at XtalPi. Dr.Jiang has 14 years of experience in biopharmaceutical R&D, with expertise in managing external translational science collaborations between academia, industry and contract research organizations. Prior to joining XtalPi, Dr. Jiang held the role of Director of Asia R&D strategy and Associate Scientific Director at Genzyme, where he led cross-functional R&D collaborations and projects in Asia and conducted external consultation for various companies on R&D strategy and processes. His completed his postdoctoral fellowship of hematology and oncology at Harvard Medical School, and has worked as project manager at China’s National Institute for the Control of Pharmaceutical and Biological Products (NICPBP, NIFDC), CFDA.
Dr. Jiang earned his Ph.D. in molecular biology from University of Tennessee-Health Science Center and M.D. from Shanghai Medical University (now Shanghai Medical College of Fudan University).
Xiaoyu Tian, PhD
Dr. Xiaoyu Tian joined VcanBio Center for Translational Biotechnology Co. in 2017 as Vice President, Product Development and is responsible for advancing all in-house and partnered drug development programs. With more than 20 years experiences in drug discovery and development at both academic and industrial settings, Dr. Tian is a technical expert in the molecular/structural biophysics-guided drug discovery and nanoparticle design for targeted drug delivery. He was formerly a senior research investigator at Bristol-Myer-Squibb, where he contributed to anti-viral and immune-oncology programs. Dr. Tian was a serial entrepreneur in the development of a pipeline of medical imaging diagnostics/devices, and the concurrent development of therapeutical products. He served as co-founder and R&D director of Beijing Beilu Pharmaceuticals, co-founder and President of Essenix Pharmaceuticals and cofounder and President of ADetect Diagnostics. He has been a senior consultant to HitGen Ltd and involved in early work at BioHermes Technologies on the DEL and IVD technologies for pharmaceutical applications. He is also an adjunct faculty member at Center for Drug Discovery, Northeastern University, where he contributes to explore the science of medicinal implications of Cannabis and the function of human endocannabinoid system. He received his Ph.D. in Pharmaceutical Sciences from the University of Connecticut, his BS and MS degrees in Quantum Electronics from Peking University, and a NIH post-doctoral fellowship on drug abuse.
Jeff Clark, J.D.& M.D.
(Jeff is also among those drafted the ground breaking CRISPR/Cas9 gene editing patent.)
Jeff Clark, M.D., J.D. is an associate at DLA Piper with a focus on patent litigation and the defense of pharmaceutical, life science and medical device companies in a variety of cases, including multi-district product liability litigation. Jeff also concentrates his practice on all aspects of patent law including patent prosecution and strategic counseling for life science start-ups, biotech, medical device and pharmaceutical companies. Jeff has extensive clinical and basic science research experience. He was a clinical research fellow in the Molecular and Vascular Medicine Unit, Renal Division (Department of Medicine), at Beth Israel Deaconess Medical Center and in the Cardiovascular Research Center (Department of Cardiology) at Massachusetts General Hospital. Jeff has authored and co-authored several publications in peer-reviewed journals and has presented at the national American Society of Nephrology Renal Week conference.
Chesley Chen, CEO,
Chesley Chen is Chief Executive Officer of Safety Partners, Inc., which provides environmental, health, and safety programs to over 200 life science and technology companies each year. Chen is a serial entrepreneur and brings extensive experience in launching and scaling up early to mid-stage health technology, life science, and financial service ventures. He has over 30 years experience in executive management, corporate strategy, client service, product development, operations, technology, and finance. He has worked for a wide range of firms including Health Dialog, Good Measures, The Warner Babcock Institute for Green Chemistry, and Goldman Sachs.
Chen holds a BS in Civil Engineering from Tufts University, an SM in Aeronautics and Astronautics from MIT, and an MBA from the Harvard Business School. As he continues on his career journey, he dedicates time to sharing his experiences about his path to CEO and his ongoing learnings. Outside of work, he devotes his time to family, rock climbing, martial arts, piano, and studying the arts and sciences. He is of Chinese heritage, the son and grandson of Chinese immigrants.
Mr. Han-kai Yi
Han-kai Yi joined TusPark (Jiangsu) as Vice General Manager in 2014. He oversees the operation, corporate relationship, corporate innovation service and incubation departments for TusParks the Jiangsu, Anhui and Zhejiang provinces, as well as the Qingpu district of Shanghai. Mr Yi has over 10 years experience developing science and technology service facilities. He is an alumnus of Nanjing University